La cadena de opciones muestra datos clave de las opciones de acciones de Halozyme Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Halozyme Therapeutics..

Halozyme Therapeutics (NASDAQ:HALO) Bolsa, Cadena de Opciones

HALOZYME THERAPEUTICS INC

Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BGNE

HALO

2 acciones del sector de la salud muestran un RSI alto, lo que podría ser una advertencia clave para los inversores centrados en el momentum.

2 acciones de atención médica que podrían desplomarse en agosto

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma">https://www.jnj.com/media-center/press-releases/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma</a>

Biotech

Government

Regulations

General

'European Commission Approves DARZALEX As The First Licensed Treatment For Patients With High-Risk Smouldering Multiple Myeloma" - Johnson & Johnson

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 2.72% on an annualized basis producing an average annual return of 14.99%. Currently, Halozyme Therapeutics has a market capitalization of $7.09 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 15 years ago, it would be worth $7,914.72 today based on a price of $57.54 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753215315_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Neutral and raises the price target from $58 to $60.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $60

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 2.0% on an annualized basis producing an average annual return of 14.27%. Currently, Halozyme Therapeutics has a market capitalization of $6.64 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 15 years ago, it would be worth $7,847.10 today based on a price of $53.89 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751898613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years

Halozyme Therapeutics Added To U.S. Large-Cap Russell 1000 Index

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 2.54% on an annualized basis producing an average annual return of 14.44%. Currently, Halozyme Therapeutics has a market capitalization of $6.72 billion. 
Buying $100 In HALO: If an investor had bought $100 of HALO stock 15 years ago, it would be worth $764.94 today based on a price of $54.54 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749768313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 5 years by 4.46% on an annualized basis producing an average annual return of 17.65%. Currently, Halozyme Therapeutics has a market capitalization of $6.59 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 5 years ago, it would be worth $2,250.31 today based on a price of $53.51 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749073516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $72 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target

Halozyme Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NYSE">HALO</a>) short percent of float has risen 12.94% since its last report. The company recently reported that it has 10.69 million shares sold short, which is 11.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Halozyme Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748451634_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Halozyme Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Halozyme Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 6.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

What's Driving the Market Sentiment Around Halozyme Therapeutics?

Looking into the current session, Halozyme Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) shares are trading at $53.85, after a 1.05% drop. Over the past month, the stock decreased by 10.78%, but over the past year, it actually went up by 26.41%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1748444424_0.png" alt="Past Year Chart" />

<h3>Halozyme Therapeutics P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Halozyme Therapeutics has a lower P/E than the aggregate P/E of 52.14 of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748444424_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Halozyme Therapeutics

Opdivo&#xAE; is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo&#xAE; (nivolumab) subcutaneous formulation developed with ENHANZE&#xAE;, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20),&nbsp;for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy&#xAE; (ipilimumab)&nbsp;combination therapy, or in combination with chemotherapy or cabozantinib.
"The European approval of Opdivo SC represents an advancement for certain cancer patients, who now have the option to receive their Opdivo as a 3-to-5-minute SC injection," said Dr. Helen Torley, president and chief executive officer of Halozyme. "This approval is just one of the 11 growth catalysts for our commercialized SC products expected this year."
The positive EC decision is supported by positive results from the Phase 3 CheckMate -67T trial. For more information on the study and its findings, please view Bristol Myers Squibb's press release issued on May 28, 2025.
The approval by the EC is valid in all 27 member states of the European Union (EU), as well as Iceland, Liechtenstein and Norway.&nbsp;
On December 27, 2024, subcutaneous nivolumab and hyaluronidase-nvhy, marketed under the brand name Opdivo Qvantig&#x2122;, was approved by the U.S. Food and Drug Administration.

Halozyme Says Bristol Myers Squibb Secures EC Approval For Opdivo Subcutaneous Formulation Developed With ENHANZE

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/25/05/45171636/exclusive-aprils-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-apple-palantir-nvidia-stocks-rank" target="_blank" rel="noreferrer noopener">EXCLUSIVE: April's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Apple, Palantir, Nvidia Stocks Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending May 23:
Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>): The biotech company saw increased interest from readers during the week, which comes a couple weeks after first-quarter financial results. The company <a href="https://ir.halozyme.com/news/news-details/2025/HALOZYME-RAISES-2025-FINANCIAL-GUIDANCE-RANGES-AND-REPORTS-STRONG-FIRST-QUARTER-2025-RESULTS/default.aspx">beat </a>analyst estimates for both earnings per share and revenue in the quarter. Halozyme also announced a new $250 million share buyback and raised full-year guidance. The company highlighted three blockbuster brands and four recently launched products. The company sees several growth catalysts coming in the future months through owned drugs and partnerships. Analysts were mixed on the stock after financial results with Morgan Stanley<a href="https://www.benzinga.com/quote/HALO/analyst-ratings"> downgrading the stock</a> and Wells Fargo raising the price target. The stock was up around 5% over the last week, as shown on the <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523">Benzinga Pro chart</a> below.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523"><img loading="lazy" decoding="async" width="995" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173420/Screenshot-424.png" alt="" class="wp-image-926666" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173420/Screenshot-424.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173420/Screenshot-424-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173420/Screenshot-424-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Tradeweb Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>): The fixed income trading company saw increased interest from readers during the week. The company <a href="https://investors.tradeweb.com/news-releases/news-release-details/tradeweb-reports-april-2025-total-trading-volume-578-trillion">reported </a>April metrics recently with average daily volume for the month hitting $2.7 trillion, up 38.6% year-over-year. Tradeweb saw several records in the month including average daily volume for US government bonds, municipal bonds, US ETFs and more. Tradeweb analysts have <a href="https://www.benzinga.com/quote/TW/analyst-ratings">raised the price targets</a> on the stock and this one could be one to watch in June with the company presenting at the Piper Sandler conference on June 5. The company's next quarterly results could see strong results and raised guidance if the trends from April continue.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523"><img loading="lazy" decoding="async" width="997" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173438/Screenshot-425.png" alt="" class="wp-image-926667" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173438/Screenshot-425.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173438/Screenshot-425-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173438/Screenshot-425-768x384.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
AMETEK Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>): The autonomous industrial company saw strong interest during the week, likely due to a recently announced acquisition and quarterly financial results. AMETEK's first quarter <a href="https://investors.ametek.com/news-releases/news-release-details/ametek-announces-first-quarter-results-3">saw </a>earnings per share beat analyst estimates, marking more than 10 straight quarters of beats, while sales just missed analyst estimates. The company said it was pleased with the first quarter and despite headwinds like macro uncertainties and tariffs, sees a strong fiscal year. The company also announced it will <a href="https://investors.ametek.com/news-releases/news-release-details/ametek-acquire-faro-technologies">acquire </a>FARO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) at an enterprise value of $920 million. The acquisition will be done using stock and cash and is expected to boost its precision segment. Faro has annual sales of around $340 million. The earnings and acquisition saw interest increase in the company, which puts this one on the watchlist as its operations with autonomous tools could be one of the fast-growing segments.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173451/Screenshot-426.png" alt="" class="wp-image-926668" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173451/Screenshot-426.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173451/Screenshot-426-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173451/Screenshot-426-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>): The utility company <a href="https://investors.alliantenergy.com/News--Presentations/news/news-details/2025/Alliant-Energy-Announces-First-Quarter-2025-Results/default.aspx">reported </a>first-quarter financial results on May 8 with earnings per share and revenue beating analyst estimates, marking three straight quarters of double beats. The company also reaffirmed its full-year guidance and announced new details on financing plans. The company owns Interstate Power and Light Company and Wisconsin Power and Light Company, providing electric to around one million customers and natural gas to around 430,000 customers in the Midwest. Jeffries <a href="https://www.benzinga.com/quote/LNT/analyst-ratings">upgraded the stock</a> from Hold to Buy after the financial results.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523"><img loading="lazy" decoding="async" width="997" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173504/Screenshot-427.png" alt="" class="wp-image-926669" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173504/Screenshot-427.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173504/Screenshot-427-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173504/Screenshot-427-768x384.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Ares Acquisition Corporation II (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AACT#NYSE">AACT</a>): Several SPACs saw increased interest from readers during the week and higher share prices. Ares Acquisition<a href="https://www.benzinga.com/markets/equities/25/04/44809515/george-soros-cathie-wood-backed-autonomous-trucking-firm-kodiak-robotics-set-to-go-public-via-spac-merger-to-tap-4-trillion-market"> announced a merger</a> with autonomous trucking company Kodiak Robotics. Increased interest for the SPAC could be due to the autonomous space seeing a boost from a recent test drive from Aurora and anticipation for Tesla's robotaxi launch in June. Kodiak says it has logged over 2.6 million autonomous driving miles in "real-world conditions." Investors in the company and SPAC merger deal includes Ares, Soros Fund Management and Ark Investments. The merger is expected to be completed in the second half of 2025.  
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523"><img loading="lazy" decoding="async" width="997" height="511" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173526/Screenshot-428.png" alt="" class="wp-image-926670" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173526/Screenshot-428.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173526/Screenshot-428-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23173526/Screenshot-428-768x394.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0523" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/04/45029510/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-62" target="_blank" rel="noreferrer noopener">April 25</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45183831/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-63" target="_blank" rel="noreferrer noopener">May 2</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45335286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-64" target="_blank" rel="noreferrer noopener">May 9</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45482435/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-65">May 16 </a></li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/04/45112477/exclusive-if-meta-is-forced-to-divest-instagram-whatsapp-or-facebook-43-pick-this-standout" target="_blank" rel="noreferrer noopener">EXCLUSIVE: If Meta Is Forced To Divest Instagram, WhatsApp, Or Facebook, 43% Pick This Standout</a></li>
</ul>

Exclusives

AACT

FARO

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) rose sharply during Friday's session after the <a href="https://www.benzinga.com/quote/EVLV">company announced preliminary first-quarter financial results.</a>
The company said it expects revenue growth of 40%+ in the first quarter.
Evolv Technologies shares jumped 21% to $5.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) jumped 33.7% to $12.34 after the company reported better-than-expected quarterly EPS results.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 30.2% to $1.64. NWTN announced the appointment of Mr. Benjamin Zhai as Executive Director of the Board and Global Chief Executive Officer.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) rose 29% to $22.70 after a court decision ruled in favor of the company regarding patent infringement claims over Nuplazid.</li>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) gained 24.7% to $1.3596.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 18.5% to $77.95 after Nvidia disclosed it added a stake in the company via a 13F filing equating to approximately 24.18 million shares. Additionally, JP Morgan and Needham raised their respective price targets on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) gained 18.5% to $6.64.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) rose 14.4% to $36.36.</li>
<li>Archer Aviation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>) surged 10.3% to $13.45.</li>
<li>Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) rose 7.5% to $15.59. Vipshop will announce first quarter 2025 financial results on May 20.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7% to $430.00.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose 6.8% to $261.17 after the company announced a partnership with Webull Pay to power crypto experiences. Additionally, Benchmark raised its price target on the stock from $252 to $301.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 5% to $51.35.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45462276/applied-materials-flowers-foods-and-3-stocks-to-watch-heading-into-friday">Applied Materials, Flowers Foods And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>
Photo via Shutterstock

Movers

ACAD

ACHR

APLD

COIN

CRWV

EVLV

NWTN

QUBT

SMLR

VIPS

Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday

Morgan Stanley analyst Vikram Purohit downgrades Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) from Overweight to Equal-Weight and lowers the price target from $73 to $62.

Downgrades

Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62

<h3>Gainers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 57.2% to $2.94 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock rose 42.98% to $1.58. The market value of their outstanding shares is at $59.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 40.9% to $1.03. The company's market cap stands at $53.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock increased by 16.2% to $4.41. The company's market cap stands at $255.5 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 15.92% to $64.0. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 15.15% to $1.9. The company's market cap stands at $95.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 95.5% to $0.02 during Tuesday's after-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 44.08% to $0.07. The company's market cap stands at $1.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 36.9% to $296.59. The company's market cap stands at $3.8 billion. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock fell 24.91% to $50.0. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock declined by 23.96% to $10.41. The market value of their outstanding shares is at $62.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) shares decreased by 20.39% to $0.82. The company's market cap stands at $54.6 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

ATPC

AXDX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KDLY

LUCY

OMER

PLRZ

VANI

12 Health Care Stocks Moving In Tuesday's After-Market Session

WIIM

Halozyme Therapeutics shares are trading lower after Leerink Partners downgraded the stock from Market Perform to Underperform and announced a price target of $47.

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday.
The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&amp;P 500 also rose, gaining, 0.86% to 5,894.52.
Check This Out: <a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares jumped by 2.3% on Tuesday.
In trading on Tuesday, health care stocks fell by 2.5%.
Top Headline
Consumer prices in the U.S. eased faster than expected in April, with fresh tariffs introduced by President Donald Trump appearing not to have a swift and tangible impact on the cost of living.
The Consumer Price Index (CPI) was 2.3% higher compared to a year ago, the Bureau of Labor Statistics said Tuesday, compared to economists&#8217; expectations of 2.4% and the previous reading.
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet falling short of a 0.3% forecasted.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 165% to $14.01 after the company announced it presented studies on HCW9206.</li>
<li>Shares of Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) got a boost, surging 33% to $3.1749 after the company reported better-than-expected first-quarter sales results.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares were also up, gaining 116% to $1.6001 after the company issued a year-over-year increase in its FY25 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) shares dropped 17% to $29.90 following first-quarter financial results.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 81% to $0.1345 after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) was down, falling 26% to $49.26. Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and announced a $47 price target.</li>
</ul>
Commodities In commodity news, oil traded up 2.9% to $63.75 while gold traded up 0.8% at $3,253.80.
Silver traded up 1.6% to $33.130 on Tuesday, while copper rose 2.1% to $4.7180.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.12%, while Spain's IBEX 35 Index rose 0.83%. London's FTSE 100 fell 0.02%, Germany's DAX 40 gained 0.31% and France's CAC 40 gained 0.30% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.43%, Hong Kong's Hang Seng Index dipping 1.87%, China's Shanghai Composite Index gaining 0.17% and India's BSE Sensex falling 1.55%.
Economics
The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of 2.4%.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

AFMD

HCWB

LOBO

MVST

XENE

Crude Oil Gains 3%; US Inflation Eases In April

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 91.4% to $0.03 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELU

CNSP

HUMA

SGMO

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

Leerink Partners downgrades Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) from Market Perform to Underperform and announces $47 price target.

Leerink Partners Downgrades Halozyme Therapeutics to Underperform, Announces $47 Price Target

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an average annual return of 15.92%. Currently, Halozyme Therapeutics has a market capitalization of $8.38 billion. 
Buying $100 In HALO: If an investor had bought $100 of HALO stock 15 years ago, it would be worth $921.02 today based on a price of $68.02 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746801014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Press Releases

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Earnings

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme to Report Second Quarter 2025 Financial and Operating Results

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Comments

Halozyme Therapeutics

Halozyme Therapeutics (HALO) Opciones

Halozyme Therapeutics (NASDAQ:HALO) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL